ClinicalTrials.gg
CompletedNCT00868452Updated Apr 17, 2014Results posted

Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)

A Phase 3 interventional study of lurasidone + (lithium or divalproex) and Placebo + (lithium or divalproex) in Bipolar Depression, sponsored by Sumitomo Pharma America, Inc.. Completed at 71 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-04-17.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
348
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing lurasidone in Bipolar Disorder — 2 open to participants now, 2 under way, none of them phase 3. lurasidone · Bipolar Disorder.

Enrollment
9th of 17
348 · median 348
Started
2009
with 2 others
Phase 3
11 of 17
none open now
Registered
1st of 17
by date
Lead sponsor
8 of 17
Sumitomo Pharma America, Inc.

Among the 17 studies testing lurasidone in Bipolar Disorder, this one is the 9th largest by enrollment, is one of 3 that started in 2009, is one of 11 in phase 3, and was the 1st registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

2 of the 17 studies testing lurasidone in Bipolar Disorder are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing lurasidone in Bipolar Disorder, or all of them as a file.
02

Study summary

This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe when added to treatment with lithium or Divalproex for the treatment of patients with bipolar I depression.

03

Conditions studied

  • Bipolar Depression

Browse trials for

Keywords

  • Bipolar I
  • Latuda
  • Lurasidone
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is diagnosed with bipolar I disorder, most resent episode depressed
  • Subject must have a lifetime history of at least one bipolar manic or mixed episode
  • Subject must be taking lithium or divalproex at least 28 days prior to screening

Exclusion criteria

Exclusion Criteria:

  • History of nonresponse to an adequate (6-week) trial of three or more antidepressants (with or without mood stabilizers) during the current episode
  • Subject has been hospitalized for a manic or mixed episode within 60 days prior to randomization
  • Imminent risk of suicide or injury to self, others, or property
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
348 participants (actual)

Study arms

  • Experimental
    Lurasidone

    Drug: lurasidone + (lithium or divalproex)

  • Placebo comparator
    Placebo

    Drug: Placebo + (lithium or divalproex)

Interventions

  • Druglurasidone + (lithium or divalproex)

    Drug page: Lurasidone

    lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7.

  • DrugPlacebo + (lithium or divalproex)

    20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)

    MADRS total score ranges from a minimum of 0 to a maximum of 60. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.

    Time frame: Baseline, Week 6

Secondary outcomes

  1. Mean Change From Baseline to Endpoint (Week 6) in: Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)

    CGI-EP-S depression score ranges from a minimum of 0 to a maximum of 7. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.

    Time frame: Baseline Week 6

  2. Mean Change From Baseline to Endpoint (Week 6) in: Sheehan Disability Scale (SDS) Total Score

    STS total score ranges from a minimum of 0 to a maximum of 30. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.

    Time frame: Baselin Week 6

07

Results

Posted Apr 2, 2013

Participant flow

5/11/2009 - 1/9/2012

Participant flow — Overall Study
MilestoneLurasidonePlacebo
Started183165
Completed143136
Not completed4029

Outcome measures

PrimaryMean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)

MADRS total score ranges from a minimum of 0 to a maximum of 60. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)
units on a scaleLurasidonePlacebo
Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)-17.1 ± 0.87-13.5 ± 0.91
Statistical analysis
  • Lurasidone vs Placebo · Mixed Models Analysis · p = 0.005 · Mean difference (final values): -3.6
SecondaryMean Change From Baseline to Endpoint (Week 6) in: Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)

CGI-EP-S depression score ranges from a minimum of 0 to a maximum of 7. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.

Time frame:
Baseline Week 6
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline to Endpoint (Week 6) in: Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)
units on a scaleLurasidonePlacebo
Mean Change From Baseline to Endpoint (Week 6) in: Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)-1.96 ± 0.104-1.51 ± 0.109
Statistical analysis
  • Lurasidone vs Placebo · Mixed Models Analysis · p = 0.003 · Mean difference (final values): -0.44
SecondaryMean Change From Baseline to Endpoint (Week 6) in: Sheehan Disability Scale (SDS) Total Score

STS total score ranges from a minimum of 0 to a maximum of 30. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.

Time frame:
Baselin Week 6
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline to Endpoint (Week 6) in: Sheehan Disability Scale (SDS) Total Score
units on a scaleLurasidonePlacebo
Mean Change From Baseline to Endpoint (Week 6) in: Sheehan Disability Scale (SDS) Total Score-9.5 ± 0.78-7.0 ± 0.81
Statistical analysis
  • Lurasidone vs Placebo · ANCOVA · p = 0.012 · Mean difference (final values): -2.6

Adverse events

Collected over Adverse event reporting begins at time of informed consent signature and continues until patient discontinuatiion - 6 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lurasidone—2/183 (1.1%)73/183 (39.9%)
Placebo—2/163 (1.2%)51/163 (31.3%)
Most frequent serious events
Most frequent serious events
EventLurasidonePlacebo
Suicidal IdeationPsychiatric disorders1/1831/163
Femur FractureInjury, poisoning and procedural complications0/1831/163
DepressionPsychiatric disorders1/1830/163
Most frequent other events
Most frequent other events
EventLurasidonePlacebo
NauseaGastrointestinal disorders32/18318/163
HeadacheNervous system disorders19/18320/163
SomnolenceNervous system disorders17/1837/163
TremorNervous system disorders15/1837/163
AkathisiaNervous system disorders14/1837/163
InsomniaPsychiatric disorders13/1839/163
DiarrheaGastrointestinal disorders8/18311/163

Baseline characteristics

Data for full analysis set is provided (intent-to-treat population)

Age, Categorical
Age, Categorical(Participants)LurasidonePlaceboTotal
<=18 years011
Between 18 and 65 years178155333
>=65 years156
Age, Continuous
Age, Continuous(years)LurasidonePlaceboTotal
Mean41.0 ± 11.5342.6 ± 11.7541.7 ± 11.65
Sex: Female, Male
Sex: Female, Male(Participants)LurasidonePlaceboTotal
Female8676162
Male9385178
Region of Enrollment
Region of Enrollment(participants)LurasidonePlaceboTotal
France8816
United States5852110
Czech Republic272148
Poland9615
Ukraine111223
Romania235
South Africa10818
Russian Federation91019
Germany246
India433780
08

Study locations

71 sites
  • Woodland International Research Inc.
    Little Rock, Arkansas 72211, United States
  • South Coast Clinical Trials, Inc.
    Anaheim, California 92804, United States
  • Catalina Research Institute
    Chino, California 91710, United States
  • Synergy Escondido
    Escondido, California 92025, United States
  • Collaborative Neuroscience Network Inc.,12772 Valley View Street
    Garden Grove, California 92645, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • University of California at Irvine Medical Center
    Orange, California 92868, United States
  • CNRI - Los Angeles LLC,8309 Telegraph Road
    Pico Rivera, California 90660, United States
  • CNRI - San Diego, LLC
    San Diego, California 92102, United States
  • Stanford University School of Medicine
    Stanford, California 94305, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Depression and Anxiety Disorders Research Institue
    Tampa, Florida 33613, United States
  • American Medical Research Inc.,1200 Harger Road Suite 415
    Oak Brook, Illinois 60523, United States
  • American Medical Research, Inc., 1200 Harger Road Suite 415
    Oak Brook, Illinois 60523, United States
  • J. Gary Booker, MD
    Shreveport, Louisiana 71104, United States
  • Sheppard Pratt Health System,6501 North Charles Street
    Baltimore, Maryland 21285, United States
  • Capital Clinical Research,5515 Security Lane, Suite 525
    Rockville, Maryland 20852, United States
  • Midwest Research Group
    St. Charles, Missouri 63301, United States
  • Albuquerque Neuroscience Inc.,101 Hospital Loop, Suite 209
    Albuquerque, New Mexico 87109, United States
  • Lake Charles Clinical Trials LLC,700 Spring Forest Road
    Raleigh, North Carolina 27609, United States
  • Richard H. Weisler , M.D., PA.,& Associates, 700 Spring Forest Road, Suite 125
    Raleigh, North Carolina 27609, United States
  • University of Cincinnati
    Cincinnati, Ohio 45219, United States
  • Mood Disorders Program-UHCMC
    Cleveland, Ohio 44106, United States
  • MetroHealth System
    Cleveland, Ohio 44122, United States
  • Midwest Clinical research Center, One Elizabeth Place, Suite G-3
    Dayton, Ohio 45408, United States
  • CRI Worldwide, LLC
    Philadelphia, Pennsylvania 19139, United States
  • FutureSearch Clinical Trials, LLC., 4200 Marathon Blvd., Suite 200
    Austin, Texas 78756, United States
  • Psychiatricka ambulance
    Brno - mesto, 602 00, Czech Republic
  • BIALBI s.r.o. Psychiatricke oddeleni
    Litomerice, 412 01, Czech Republic
  • Clintrial, s.r.o.
    Praha, 10 100 00, Czech Republic
  • Medical Services Prague s.r.o.
    Praha, 6 160 00, Czech Republic
  • Psychiatricka ambulance Prosek
    Praha, 9 190 00, Czech Republic
  • Hopital Caremeau, Service de Psychiatrie A
    Nimes Cedex, 30 30029, France
  • Zans Ritter, Marcel
    Orvault, 44700, France
  • Jana Thomsen
    Berlin BE, 10245, Germany
  • SV Medical College
    Tirupati, Andh Prad 517507, India
  • Vijayawada Institute of Mental Health and Neurosciences, Psychiatry
    Vijaywada, Andh Prad 520002, India
  • Samvedna Hospitals
    Ahmedabad, Gujarat 380006, India
  • Sheth Vadilal Sarabhai General Hospital
    Ahmedabad, Gujarat 380006, India
  • Mental Illness Treatment Rehabilitation Foundation (MITR)
    Ahmedabad, Gujarat 380013, India
  • Shree Hatkesh Health Foundation
    Junagadh, Gujarat 362001, India
  • Spandana Nursing Home
    Bangalore, Karna 560010, India
  • Sujata Birla Hospital & Research Centre
    Nashik, Mahara 422101, India
  • R.K. Yadav Memorial Mental Health & De-Addiction Hospital
    Jaipur, Rajasthan 302021, India
  • Manobal Med. Research Centre
    Lucknow, Uttar Prad 226006, India
  • Cosmos Hospitals-Delhi Psychiatry Center-Dept. of Psychiatry
    Delhi, 110092, India
  • ZOZ Poradnia Zdrowia Psychicznego
    Chelmno, 86-200, Poland
  • Praktyka Lekarska Sensorium S.M.O.
    Skorzewo, 60-185, Poland
  • Wojewodzki Szpital Brodnowski SP ZOZ
    Warszawa, 03-242, Poland
  • Spitalul Clinic de Urgenta Militar Central "Prof. Dr. Carol" Psihiatrie
    Bucuresti, 010825, Romania
  • Spitalul Clinic de Psihaiatrie Prof. Dr. Alexandru Obregia
    Bucuresti, 041914, Romania
  • Spitalul Clinic Judetean de Urgenta Cluj
    Cluj-Napoca, 400012, Romania
  • Spitalul Clinic de Neuropsihiatrie Craiova
    Craiova, 200620, Romania
  • Spitalul Clinic de Neurologie si Psihiatrie Oradea
    Oradea, 410154, Romania
  • Spitalul Judetean de Urgenta Pitesti Sectia de Psihiatric
    Pitesti, 110069, Romania
  • Russian State Medical University
    Moscow, 117997, Russian Federation
  • Moscow Medical Academy named I.M. Sechenov
    Moscow, 119435, Russian Federation
  • City Psychiatric Hospital #2 of St. Nikolay Chudotvorets
    St. Petersburg, 190121, Russian Federation
  • Bekhterev Scientific Research Psychoneurological Institute
    St. Petersburg, 193019, Russian Federation
  • Psychoneurology Dispensary #4
    St. Petersburg, 197110, Russian Federation
  • LLC International Medical Centre "SOGAZ"
    St. Petersburg, 198035, Russian Federation
  • Cape Trial Centre
    Cape Town, W. Cape, 7530, South Africa
  • Paarl Medical Centre
    Paarl, W. Cape, 7646, South Africa
  • Clinika
    Port Elizabeth, E. Cape, 6000, South Africa
  • Dey Clinic
    Pretoria, Gauteng, 0181, South Africa
  • Vereeniging Medi-Clinic
    Vereeniging, Free State, 1941, South Africa
  • Reg. Clinic Psych. Hosp., Dept 11, DNMU n.a.M. Gorkiy
    Donetsk, 83008, Ukraine
  • Odesa Regional Psychoneurological Dispensary
    Odesa, 65014, Ukraine
  • Reg. Ci.Ps.H.n.a.O.F.Maltsev, Fem.Ac.Gen.Ps. D.5B,HESIU UM
    Poltava, 36006, Ukraine
  • CRI"Cl. Psych.Hosp.#1, Fem Psych.Dept.#2, Male Psych.Dept.#1
    Simferopol, 95006, Ukraine
  • Reg. Psych. Hosp. n.a. O.Yuschenko, Dept. #21, VNMUn.a.M. Pirog
    Vinnitsia, 21005, Ukraine
09

References and documents

Publications

  • Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J, Calabrese JR. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014 Feb;171(2):169-77. doi: 10.1176/appi.ajp.2013.13070985. PubMed 24170221 ↗
  • Sajatovic M, Forester BP, Tsai J, Kroger H, Pikalov A, Cucchiaro J, Loebel A. Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression: Post Hoc Analysis of 2 Double-Blind, Placebo-Controlled Studies. J Clin Psychiatry. 2016 Oct;77(10):e1324-e1331. doi: 10.4088/JCP.15m10261. PubMed 27529375 ↗
  • Rajagopalan K, Bacci ED, Ng-Mak D, Wyrwich K, Pikalov A, Loebel A. Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials. BMC Psychiatry. 2016 May 23;16:157. doi: 10.1186/s12888-016-0865-y. PubMed 27215976 ↗
  • Chapel S, Chiu YY, Hsu J, Cucchiaro J, Loebel A. Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis. Clin Ther. 2016 Jan 1;38(1):4-15. doi: 10.1016/j.clinthera.2015.11.013. Epub 2015 Dec 22. PubMed 26730454 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Dec 2011 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2013, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2009
First posted
Mar 25, 2009
Start
Apr 2009
Primary completionActual
Dec 2011
CompletionActual
Jan 2012
Results first posted
Apr 2, 2013
Last update
Apr 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00868452
Responsible party
Sponsor
First posted
Mar 25, 2009
Start date
Apr 2009
Primary completion
Dec 2011
Completion
Jan 2012
Results posted
Apr 2, 2013
Last update
Apr 17, 2014

Study contacts

Medical Director, MD
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion